The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global spine biologics market size reached US$ 1.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2027, exhibiting a growth rate (CAGR) of 4.32% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Spine biologics are materials that alter the surrounding environment through active cellular processes. They promote growth and differentiation and aid in the repair and healing of an injury. They also reduce the frequency of primary or additional surgical procedures and decrease the disruption of soft tissue. At present, a wide variety of spine biologics are used as an alternative to conventional treatments. For instance, pedicle screws and rods find application in a spine fusion procedure to provide spinal stabilization, thereby promoting healing. Moreover, continuous advancements are promoting the repair and regeneration of cartilaginous and bony structures.
Spine fusion is utilized as a tool in the treatment of spine trauma, tumors, and degenerative disorders. However, its poor outcomes can lead to serious complications among patients. This, in confluence with a significant increase in the number of individuals with acute and chronic conditions represents one of the key factors positively influencing the use of spine biologics around the world. Spine biologics impact fusion at the cellular level, which helps achieve successful arthrodesis in the treatment of symptomatic deformity or instability. Moreover, there is a rise in the geriatric population globally, which is more susceptible to musculoskeletal conditions. This, along with the growing prevalence of orthopedic conditions, is catalyzing the demand for spine biologics worldwide. Apart from this, the escalating demand for non-surgical procedures is encouraging the use of spinal biologics in minimally invasive lumbar surgeries. Spine biologics are also gaining traction as a replacement for metal hardware and in individual natural bone grafts or allografts. Furthermore, the growing access to healthcare services on account of inflating income levels is contributing to market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global spine biologics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, surgery type and end user.
Breakup by Product:
Breakup by Surgery Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Arthrex Inc, Alphatec Holdings Inc., Exactech Inc, Johnson & Johnson, Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V. and Zimmer Biomet.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Surgery Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Arthrex Inc, Alphatec Holdings Inc., Exactech Inc, Johnson & Johnson, Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V. and Zimmer Biomet|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at